Monkeypox is related to the virus that causes smallpox and occurs mostly in central and western Africa.
It is less severe than smallpox and can be transmitted from infected animals to humans or from person to person.
But monkeypox does not spread easily between people.
Human-to-human transmission occurs through close contact with rashes, blisters, or sores on the skin.
The rash can vary from person to person and may appear as pimples, blisters or sores, especially on the genital and perianal areas of affected people.
The infection can spread between people through bodily fluids, including respiratory droplets from coughing or sneezing (this is less common and usually only happens through prolonged personal contact)
It can also be transmitted through contaminated items such as linens and towels.
Monkey pox is usually not life-threatening. Infection with the virus usually causes mild illness, and most people recover within a few weeks.
It may also have more prominent symptoms, such as a painful rash or sores in the throat or rectum.
Some people can become seriously ill and suffer complications and potentially death.
Young children and pregnant women are also at higher risk of developing complications.
Problems can include secondary infection, scarring, sepsis (infection of the bloodstream), pneumonia (infection of the lungs), and encephalitis (inflammation of the brain).
A complete vaccination schedule with JYNNEOS® requires two doses injected at least 28 days apart.
People at high risk of monkeypox infection who received a dose of smallpox vaccine more than ten years ago are recommended to receive only one dose of the new smallpox vaccine.
People who have been infected with monkeypox virus during this outbreak are not recommended to be vaccinated at this time because they are likely to have immune protection against the infection.
There are no studies directly evaluating the effectiveness of JYNNEOS® in humans infected with smallpox virus or monkeypox virus.
However, studies have shown that people given it produced antibodies at a level expected to provide protection against smallpox.
Maximum protection occurs approximately two weeks after the second dose of this vaccine.
Common side effects reported after receiving the vaccine include: injection site pain, redness, swelling or itching, muscle aches, headache, tiredness, nausea, chills, and fever
Source: Health.gov.au, GP News